Sunday’s Midday Stock Update: Whiting Petroleum (WLL), uniQure (QURE), Cytokinetics (CYTK), TG Therapeutics (TGTX), Dynavax (DVAX)

By Carrie Williams

So far Sunday, December 15, NASDAQ is up 0.32% and the S&P is up 0.45%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Whiting Petroleum (WLLResearch Report), uniQure (QUREResearch Report), Cytokinetics (CYTKResearch Report), TG Therapeutics (TGTXResearch Report) and Dynavax (DVAXResearch Report).

Whiting Petroleum is down -8.23% in midday trading to $5.91. Shares opened today at $6.44. The company has a 52-week low of $4.29 and a 52-week high of $30.94. On the Street’s front, the average 12-month analyst price target for the stock is $8.36, marking a 29.81% potential upside from current levels. In a report issued on December 6, Barclays analyst William S. Thompson maintained a Hold rating on WLL, with a price target of $5.00, which represents a potential downside of 22% from where the stock is currently trading. Separately, on December 2, R. F. Lafferty’s Jaime Perez maintained a Buy rating on the stock and has a price target of $12.00. In the last 30 days, insiders have sold $3,019 worth of WLL shares.

uniQure is up 7.73% in midday trading to $73.97. Shares opened today at $68.66. The company has a 52-week low of $24.07 and a 52-week high of $82.49. On the Street’s front, the average 12-month analyst price target for the stock is $86.00, marking a 25.25% potential upside from current levels. In a report issued on December 10, Mizuho analyst Difei Yang reiterated a Buy rating on QURE, with a price target of $90.00, which implies an upside of 31% from current levels. Over the last 3 months, the insider sentiment on uniQure has been negative based on 46 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Cytokinetics is up 6.71% in midday trading to $10.65. Shares opened today at $9.98. The company has a 52-week low of $5.75 and a 52-week high of $14.94. On the Street’s front, the average 12-month analyst price target for the stock is $24.67, marking a 147.19% potential upside from current levels. In a report issued on November 19, H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on CYTK, with a price target of $30.00, which represents a potential upside of 201% from where the stock is currently trading. In the last 30 days, insiders purchased $3.23M worth of CYTK shares. Over the last 3 months, the insider sentiment on Cytokinetics has been positive based on 24 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

TG Therapeutics is up 6.32% in midday trading to $10.10. Shares opened today at $9.50. The company has a 52-week low of $3.32 and a 52-week high of $10.79. On the Street’s front, the average 12-month analyst price target for the stock is $18.50, marking a 94.74% potential upside from current levels. In a report issued on December 10, H.C. Wainwright analyst Edward White reiterated a Buy rating on TGTX, with a price target of $20.00, which implies an upside of 111% from current levels.

See today’s analyst top recommended stocks >>

Dynavax is up 5.65% in midday trading to $6.92. Shares opened today at $6.55. The company has a 52-week low of $2.60 and a 52-week high of $12.42. On the Street’s front, the average 12-month analyst price target for the stock is $16.50, marking a 151.91% potential upside from current levels. In a report issued on December 3, William Blair analyst Matt Phipps maintained a Buy rating on DVAX.

Trending Stocks Based on Insider Activity >>